ArticleNature biotechnology2023
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.
Open access · greenAbstract read
In one paragraph
Article in Nature biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
26.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Pooled it
- Preclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulation.Annals of medicine · 2026Review
- Review
- Pediatric AML CAR T cell therapy.Molecular therapy. Oncology · 2026Review
- Putting the I in AML: Artificial Intelligence and Machine Learning in Acute Myeloid Leukemia.Cells · 2026Review
- Role of pyroptosis in melanoma: Molecular mechanisms and therapeutic potentials.Apoptosis : an international journal on programmed cell death · 2026Review
- Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy.Experimental hematology & oncology · 2026Article
- Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.Blood advances · 2026Article
- Review
- Bispecific CD37-Siglec6 CAR‑T cells exhibit enhanced anti‑leukemic activity and reduced exhaustion in acute myeloid leukemia xenograft models.Journal of translational medicine · 2026Article
- Review
- Ablation of prostaglandin ENature biomedical engineering · 2026Article
- Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy.Nature biomedical engineering · 2026Article
- CSF1R marks a subset of foetal haematopoietic multipotent progenitor cells with acute myeloid leukaemia propagation properties.Leukemia · 2026Article
- In vivo engineering of CAR-T cells: delivery strategies and clinical translation.Biomarker research · 2026Review
- Messenger RNA therapy in bone and joint diseases: Rationale, delivery systems, and applications.Biomaterials translational · 2026Article
- Algorithmically defined therapeutic targets: integrating single-cell transfer learning frameworks with small molecule drugs to reverse disease-associated cell fates.Frontiers in pharmacology · 2026Review
- Immunological barriers and engineering strategies for CAR-T cell therapy in acute myeloid leukemia.Frontiers in immunology · 2026Review
- Integrating AI, RNA Vaccines, and CAR-T Cells for Personalized Treatment.Journal of immunology research · 2026Review
- Convergence of mRNA technology and chimeric antigen receptor therapy: targeted technology optimizing targeted therapy.Journal of translational medicine · 2025Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors at 6 institutions in 1 country.
Adrian Gottschlich *Division of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.ORCID 0000-0002-2898-4182
Moritz Thomas *Institute of AI for Health, Helmholtz Munich, Neuherberg, Germany.ORCID 0000-0002-8422-2414
Ruth Grünmeier *Division of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.ORCID 0000-0002-9044-3600
Stefanie LeschDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.ORCID 0000-0003-2658-7666
Lisa RohrbacherDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Veronika IglDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.ORCID 0000-0003-4618-2383
Daria BriukhovetskaDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.ORCID 0000-0002-2073-2335
Mohamed-Reda BenmebarekDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Binje VickResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Munich, German Research Center for Environmental Health (HMGU), Munich, Germany.ORCID 0000-0003-1956-2778
Sertac DedeDepartment of Neurology, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0003-4389-3999
Katharina MüllerDepartment of Neurology, University Hospital, LMU Munich, Munich, Germany.
Tao XuDepartment of Neurology, University Hospital, LMU Munich, Munich, Germany.
Dario DhoqinaDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Florian MärklDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.ORCID 0000-0003-4285-0380
Sophie RobinsonInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
Andrea SendelhofertInstitute of Pathology, LMU Munich, Munich, Germany.
Heiko SchulzInstitute of Pathology, LMU Munich, Munich, Germany.
Öykü UmutDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Vladyslav KavakaInstitute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Christina Angeliki TsiveriotiDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Emanuele CarliniDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Sayantan NandiDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Thaddäus StrzalkowskiDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.ORCID 0000-0002-7191-0410
Theo LorenziniDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.ORCID 0000-0003-3377-032X
Sophia StockDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.ORCID 0000-0002-5072-5013
Philipp Jie MüllerDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Janina DörrDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Matthias SeifertDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.ORCID 0000-0002-6581-6196
Bruno L CadilhaDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.ORCID 0000-0001-7045-3898
Ruben BrabenecDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Natalie RöderDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Felicitas RatajDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Manuel NüeschDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Franziska ModemannDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-5897-3310
Jasmin WellbrockDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Walter FiedlerDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christian KellnerDivision of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0002-2562-6902
Eduardo BeltránMunich Cluster for Systems Neurology (SyNergy), Munich, Germany.ORCID 0000-0002-7266-4098
Tobias HeroldDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0002-9615-9432
Dominik PaquetInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0003-2065-1639
Irmela JeremiasResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Munich, German Research Center for Environmental Health (HMGU), Munich, Germany.
Louisa von BaumgartenGerman Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.ORCID 0000-0002-6634-0927
Stefan EndresDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Marion SubkleweDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Carsten MarrInstitute of AI for Health, Helmholtz Munich, Neuherberg, Germany.ORCID 0000-0003-2154-4552
Sebastian KoboldDivision of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany. sebastian.kobold@med.uni-muenchen.de.ORCID 0000-0002-5612-4673
German Center for Lung Research · DELMU Klinikum · DEHelmholtz Zentrum München · DEUniversität Hamburg · DEGerman Cancer Research Center · DELudwig-Maximilians-Universität München · DE
Funding
European Research Council 756017
Abstract
Chimeric antigen receptor T cells (CAR-T cells) have emerged as a powerful treatment option for individuals with B cell malignancies but have yet to achieve success in treating acute myeloid leukemia (AML) due to a lack of safe targets. Here we leveraged an atlas of publicly available RNA-sequencing data of over 500,000 single cells from 15 individuals with AML and tissue from 9 healthy individuals for prediction of target antigens that are expressed on malignant cells but lacking on healthy cells, including T cells. Aided by this high-resolution, single-cell expression approach, we computationally identify colony-stimulating factor 1 receptor and cluster of differentiation 86 as targets for CAR-T cell therapy in AML. Functional validation of these established CAR-T cells shows robust in vitro and in vivo efficacy in cell line- and human-derived AML models with minimal off-target toxicity toward relevant healthy human tissues. This provides a strong rationale for further clinical development.
Indexed as
Leukemia, Myeloid, AcuteTranscriptomeCell LineCell Line, TumorHumansImmunotherapy, AdoptiveT-Lymphocytes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.